Iman Mohamed, MD
Hematology & Oncology · Kalamazoo, MINPI 1942297270
Payments from drug & device makers
Across 29 payments — averaging $147.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Tosoh Bioscience, Inc.$2K
- Tempus AI, Inc$276
- Medtronic$162
- Genentech USA, Inc.$84
- GSK$82
- plus $338 from 10 others
What the payments were for
- Consulting fees$1,66539%
- Food & beverage$77918%
- Education$2025%
- Gifts$1,63238%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 3 | $1,704 |
| Tosoh Bioscience, Inc. | 3 | $1,632 |
| Tempus AI, Inc | 3 | $276 |
| Medtronic | 1 | $162 |
| Genentech USA, Inc. | 1 | $84 |
| GSK | 4 | $82 |
| Gilead | 3 | $82 |
| Johnson & Johnson | 1 | $75 |
| Novartis | 2 | $45 |
| Amgen | 2 | $31 |
| AbbVie | 1 | $25 |
| Merck | 1 | $23 |
| Mirati Therapeutics, Inc. | 1 | $22 |
| Dova Pharmaceuticals | 1 | $12 |
| Immunomedics, Inc. | 1 | $12 |
| Ipsen Biopharmaceuticals, Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMFINZI$1,665
- CORT, ST AIA-PACK$1,088
- CORTISOL, AIA-PACK Sample Diluting Sol$1,088
- ACTH, ST AIA-PACK$1,088
- ACTH, ST AIA-PACK SDS$544
- Wash Concentrate, AIA-PACK$544
- CORTISOL, AIA-PACK Calibrator Set$544
- ACTH, AIA-PACK CALIBRATOR SET$544
- NOZZLE ASSY, 360$544
- OSTEOCOOL RF ABLATION$162
How this compares
$4,278 in reported general payments places this provider in the 55th percentile of 282 hematology & oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 35 | $566,612 |
| Anastrozole | 161 | $5,867 |
| Letrozole | 75 | $4,837 |
| Dexamethasone | 45 | $737 |
| Ondansetron Hcl | 38 | $411 |
| Gabapentin | 12 | $275 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 13 | $217 |
| Pantoprazole Sodium | 12 | $120 |
| Olanzapine | 12 | $83 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Kalamazoo
- Sunil NagpalKalamazoo$197K
- Mohammad OmairaKalamazoo$79K
- Sreenivasa ChandanaGrand Rapids$19.1M
- Nehal LakhaniGrand Rapids$15M
- Hirva MamdaniDetroit$9.5M
- Jeffrey ZonderDetroit$8.2M
- Assuntina SaccoAnn Arbor$8.1M
- Abhinav DeolDetroit$4.5M
- Harsh ShahDetroit$2.6M
- Igor RybkinDetroit$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.